Daunorubicin (HCl)

Daunorubicin (HCl) is antineoplastic agent. Daunorubicin (HCl) is anthracycline antibiotic, isolated from Streptomyces peuceticus var caesius. Daunorubicin (HCl) is the first agent in this class to be isolated. Daunorubicin (HCl) is structurally almost identical to doxorubicin, lacking only a hydroxyl moiety. Daunorubicin (HCl) is among the most useful cytotoxic anticancerous drugs. Daunorubicin (HCl) is effective in the treatment of different cancers such as acute myelocytic leukemia in adults and is used in combination with different anticancerous drugs to obtain the best therapeutic results and to minimize side effects or toxicities.

Brands
DAUNOCIN D-BLASTIN DAUNOBLASTINA RD RUBILEM DAUNOTEC
Adult Dose
Dose: 30 to 45 mg/sq.meter
Single Dose: 38 (37.5)
Frequency: 24 hourly
Route: IV
Instructions: For 3 Days
Neonatal
Dose: 1 mg/sq.meter
Single Dose: 2 (2)
Frequency: As recommended.
Route: Intra Venous
Instructions: As Required
Paedriatic
Dose: 25 mg/sq.meter
Single Dose: 46 (46)
Frequency: As recommended.
Route: Intra Venous
Instructions: Once a week.For acute lyphoblastic leukaemia in combination regiments.
Characteristics
Daunorubicin (HCl) also known as Daunomycin. Daunorubicin is the derivative of Daunorubicin (HCl). It is of Natural origin and belongs to Anthracycline. It belongs to Intercalation (DNA acting) pharmacological group on the basis of mechanism of action and also classified in Antineoplastic Agent, Antibiotic pharmacological group.The Molecular Weight of Daunorubicin (HCl) is 564.00. Its pKa is 10.3.
Contraindications
Daunorubicin (HCl) is contraindicated in conditions like Heart failure,Chickenpox infection.
Effects
The severe or irreversible adverse effects of Daunorubicin (HCl), which give rise to further complications include Thrombophlebitis, Tissue necrosis, Radiation recall.Daunorubicin (HCl) produces potentially life-threatening effects which include Congestive heart failure, Bone marrow suppression, Cardiac arrhythmia, Neutropenia, Cardiomyopahty, ECG abnormalities. which are responsible for the discontinuation of Daunorubicin (HCl) therapy.The symptomatic adverse reactions produced by Daunorubicin (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Alopecia, Mucositis, Red urine, Alopecia.
Indications
Daunorubicin (HCl) is primarily indicated in conditions like Acute granulocytic leukemia, Acute leukemia, Acute lymphocytic leukemia, Kaposis sarcoma, NSAID-associated ulceration.
Interactions
Daunorubicin (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCytarabine (HCl)Mercaptopurine (Monohydrate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Inj (reconstituted soln) Store at room temperature or refrigerator. Protect from Sunlight. Use within 2 days if refrigerated and within 24 hrs if kept at room temperature.
Warnings
Daunorubicin should be used with caution in patients with pre-existing blood disorders, liver disease or heart disease. This medication must not be used during pregnancy or lactation.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.